LungLife AI
Develops AI-enabled lung disease testing technology to shorten diagnostic turnaround times for healthcare providers.
Overview
LungLife AI builds AI-enabled healthtech tools aimed at reducing the time required to test for lung disease. Its products target clinical settings where faster assessment can support earlier decision-making for patients and providers. The company is positioned as a UK healthtech challenger, with differentiation centered on applying AI to improve lung disease testing workflows. It has raised $19M in an undisclosed round announced in July 2026.
Funding History
UK healthtech challenger using AI to cut lung disease test time clinches $19M
Frequently Asked Questions
- How much has LungLife AI raised in total?
- LungLife AI has raised a total of $19M across 1 funding round.
- What does LungLife AI do?
- LungLife AI builds AI-enabled healthtech tools aimed at reducing the time required to test for lung disease. Its products target clinical settings where faster assessment can support earlier decision-making for patients and providers. The company is positioned as a UK healthtech challenger, with differentiation centered on applying AI to improve lung disease testing workflows. It has raised $19M in an undisclosed round announced in July 2026.
- Where is LungLife AI headquartered?
- LungLife AI is headquartered in London, United Kingdom.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.